https://scholars.lib.ntu.edu.tw/handle/123456789/535980
標題: | Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections | 作者: | CHIEN-CHING HUNG SHAN-CHWEN CHANG |
公開日期: | 2004 | 卷: | 54 | 期: | 5 | 起(迄)頁: | 849-853 | 來源出版物: | Journal of Antimicrobial Chemotherapy | 摘要: | We review the changes in incidences of HIV-related opportunistic infections and the safety of discontinuation of primary and secondary prophylaxis for HIV-related opportunistic infections in patients achieving immune restoration after the introduction of highly active antiretroviral therapy (HAART). HIV-related opportunistic infections continue to occur in patients who are newly diagnosed with HIV infection, those in the early course of HAART or non-adherent to HIV care and HAART, and those in whom non-HIV-related infections have emerged as a significant cause of morbidity and mortality in the post-HAART era. Clinical studies of patients with tuberculosis and HIV co-infection are reviewed to provide appropriate regimen combinations of rifamycins and antiretrovirals, which have varying degrees of drug-drug interactions that have posed challenges in the management of tuberculosis as well as HIV infection. ? The British Society for Antimicrobial Chemotherapy 2004; all rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-8844232665&doi=10.1093%2fjac%2fdkh438&partnerID=40&md5=0c45cc26e3d4859fa96ddf0b9cfc93e7 https://scholars.lib.ntu.edu.tw/handle/123456789/535980 |
ISSN: | 0305-7453 | DOI: | 10.1093/jac/dkh438 | SDG/關鍵字: | antifungal agent; antiretrovirus agent; CD4 antigen; ciprofloxacin; cotrimoxazole; cytochrome P450 reductase; efavirenz; fluconazole; indinavir; itraconazole; nelfinavir; nevirapine; Pneumococcus vaccine; proteinase inhibitor; rifabutin; rifampicin; rifamycin; ritonavir; RNA directed DNA polymerase inhibitor; saquinavir; tuberculostatic agent; AIDS related complex; antibiotic prophylaxis; bacteremia; bacterial infection; clinical trial; cryptococcosis; cryptosporidiosis; cytomegalovirus infection; disease course; hepatitis B; hepatitis C; highly active antiretroviral therapy; histoplasmosis; human; Human immunodeficiency virus; immune response; incidence; leukoencephalopathy; lobar pneumonia; lung tuberculosis; morbidity; mortality; mycobacteriosis; Mycobacterium intracellulare avium; mycosis; parasitosis; patient compliance; Pneumocystis pneumonia; review; risk reduction; systematic review; toxoplasmosis; virus infection; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Bacterial Infections; Humans; Incidence; Mycoses; Parasitic Diseases; Rifamycins; Tuberculosis; Virus Diseases |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。